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Abstract Nephrolithiasis associated with inborn metabolic
diseases is a very rare condition with some common
characteristics: early onset of symptoms, family history,
associated tubular impairment, bilateral, multiple and
recurrent stones, and association with nephrocalcinosis.
The prognosis of such diseases may lead to life threatening
conditions, not only because of unabated kidney damage
but also because of progressive extra-renal involvement,
either in a systemic form (e.g. primary hyperoxaluria type 1,
requiring combined liver and kidney transplantation), or in a
neurological form (Lesch–Nyhan syndrome leading to auto-
mutilation and disability, phosphoribosyl pyrophosphate
synthetase superactivity, which is associated with mental
retardation). Patients with other inborn metabolic diseases
present only with recurrent stone formation, such as
cystinuria, adenine phosphoribosyl-transferase deficiency,
xanthine deficiency. Finally, nephrolithiasis may be second-
arily part of some other metabolic diseases, such as glycogen
storage disease type 1 or inborn errors of metabolism leading
to Fanconi syndrome (nephropathic cystinosis, tyrosinaemia
type 1, fructose intolerance, Wilson disease, respiratory
chain disorders, etc.). The diagnosis is based on highly
specific investigations, including crystal identification, bio-
chemical analyses and DNA study. The treatment of
nephrolithiasis requires hydration as well as specific meas-
ures.Complianceisamajorissueregardingtheprogressionof
renal damage, but the overall outcome mainly depends on
extra-renal involvement in relation to the metabolic defect.
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Introduction
Nephrolithiasis may occur in many kinds of inborn
metabolic disorders, either as the initial symptom (e.g.
primary hyperoxaluria, cystinuria) or as a late event (e.g.
glycogen storage disease). Urine supersaturation may be
related to the biochemical defect itself (oxalate, cystine) or
to a secondary disorder (urate, citrate) (Table 1).
Nephrolithiasis associated with inborn metabolic dis-
eases have common characteristics: onset of the disease
during childhood, family history (consanguinity in cases of
recessive inheritance, urolithiasis among parents in cases of
dominant inheritance), associated tubular dysfunction,
bilateral stones and/or nephrocalcinosis, multiple and
recurrent stones, presence of extra-renal involvement.
Primary hyperoxalurias
Primary hyperoxaluria (PH) accounts for a wide spectrum
of diseases, ranging from occasional stone passage to
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e-mail: pierre.cochat@chu-lyon.frdramatic systemic oxalosis in infants. Two distinct inherited
enzyme defects have been related to PH1 and PH2, i.e.
alanine:glyoxylate aminotransferase (AGT) and glyoxylate
reductase/hydroxypyruvate reductase (GR/HPR), respec-
tively; in addition, patients without PH1 and PH2 have
been reported. However, PH1 is the most common and the
most challenging form.
Epidemiology of primary hyperoxaluria type 1
PH1 [online Mendelian Inheritance in Man (MIM) 259900] is
an autosomal recessive disorder (~1:120,000 live births per
yearinEurope),causedbythefunctionaldefectofthehepatic,
peroxisomal, pyridoxal phosphate-dependent enzyme AGT,
leading to oxalate overproduction; the disease occurs because
AGT activity is either absent or mistargeted to the mitochon-
dria. Since calcium oxalate is poorly soluble in urine, patients
withPH1usuallypresentwithsymptomsrelatedtotheurinary
tract. The risk of stone formation is increased when urine
oxalate exceeds 0.4 mmol/l, especially if urine calcium
concentration is elevated (i.e. more than 4 mmol/l), leading
to formation of monohydrated calcium oxalate (whewellite)
crystals. The median age of patients when symptoms first
appear is 5–6 years, and end-stage renal disease (ESRD) is
reached between 25 years and 40 years of age in half of
patients [1]. PH1 is responsible for less than 0.5% of ESRD
in children in Europe and 10–13% in countries with a high
rate of consanguineous marriages. Along with progressive
decline of glomerular filtration rate (GFR<30–50 ml/minper
1.73 m
2) due to renal parenchymal involvement, continued
overproduction of oxalate by the liver and reduced oxalate
excretion by the kidneys lead to systemic involvement
(named ‘oxalosis’), so that bone becomes the major
compartment of the poorly soluble oxalate pool (Fig. 1)[ 2].
Diagnosis of primary hyperoxaluria type 1
The combination of both clinical and sonographic signs is a
strong argument for PH1, i.e. the association of renal
calculi, nephrocalcinosis and renal impairment; in addition,
family history may bring additional information. PH1
grossly fits five presentations: (1) infantile form with early
nephrocalcinosis and kidney failure; (2) recurrent urolithia-
sis and progressive renal failure, leading to a diagnosis of
PH1 in childhood or adolescence; (3) late-onset form with
occasional stone passage in adulthood; (4) diagnosis given
by post-transplantation recurrence, and (5) pre-symptomatic
subjects with a family history of PH1 [2].
Crystalluria and infrared spectroscopy are of major interest
for identification and quantitative analysis of crystals and
stones showing whewellite (Fig. 2)[ 3]. Monohydrated
calcium oxalate accounts for 4–5% of all renal stones in
children in France, and most of them are due to PH1.
In the presence of a normal GFR, concomitant hyperoxaluria
(urine oxalate>0.5 mmol/1.73 m
2 per 24 hours) and hyper-
glycoluria (urine glycolate>0.5 mmol/1.73 m
2 per 24 hours)
are indicative of PH1. Normal reference values for spot oxalate:
creatinine ratio (mmol/mmol) are 0.2 at birth, 0.14 at 5 years of
age, 0.085 at 10 years of age and 0.06 at 15 years of age.
Inpatientswithwell-definedphenotype,genotypingcanbe
proposed in order to screen the most common mutations
according to ethnic background. Independent of diagnostic
value,mutationanalysismaybringinformationonpyridoxine
responsiveness, on complex enzyme phenotype, and, some-
times, on clinical prognosis [4, 5]. In the presence of atypical
presentation, a definitive diagnosis may sometimes require
the measurement of AGT activity in liver tissue.
DNA analysis of primary hyperoxaluria type 1
The AGXT gene is located on chromosome 2q37.3; numer-
ous mutations and polymorphisms have been identified so
far, and they play a role either in enzyme trafficking or in
clinical/biochemical phenotype. DNA analysis among differ-
Fig. 1 Bone biopsy in an adolescent with primary hyperoxaluria type
1. Examination under polarised light shows calcium oxalate crystals
Table 1 Nephrolithiasis associated with inborn metabolic diseases according to presentation and pathophysiology
Nephrolithiasis due to the metabolic defect itself Nephrolithiasis due to secondary metabolic effect
Nephrolithiasis is usually an initial/early symptom Nephrolithiasis occurs during the evolution
Primary hyperoxaluria types 1 and 2 Glycogen storage disease type 1
Cystinuria Treatment of secondary Fanconi syndrome
Disorders of purine and pyrimidine metabolism
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mutations, founder effects and phenotype–genotype correla-
tions (e.g. North-African, Spanish, Canary Island, Japanese,
Turkish, and Pakistani populations) (review in [2, 4]).
Prenatal diagnosis can be performed from DNA obtained
from chorionic villi or amniocytes.
Treatment of primary hyperoxaluria type 1
Conservative measures should be started as soon as the
diagnosis has been made, or even suspected. The aims are
to increase calcium oxalate urinary solubility and to
decrease oxalate production. Treatment should be initiated
with high fluid intake (2–3 l/m
2 per day), aiming at urine
dilution by day and night, that may require tube feeding in
young children but often fails due to non-compliance.
Inhibitors of calcium oxalate crystallisation, such as citrate
(potassium or sodium citrate, 100–150 mg/kg per day in 3–4
divided doses) or phosphate (orthophosphate, 20–60 mg/kg
per day in 3–4 divided doses), are mandatory in order to
decrease calcium absorption, and therefore calciuria, and to
decrease growth and agglomeration of calcium oxalate
crystals. Diuretics require careful management: frusemide
will increase urine output with the risk of an increased
calciuria, whereas the diuretic effect of thiazides is less
marked but is associated with an appreciable decrease in
calcium excretion. Restriction of dietary oxalate intake has
limited influence on the disease.
Pyridoxine sensitivity (i.e. > 30% reduction of urinary
oxalate excretion) is found in 10–30% of PH1 patients, so
that it must be tested early at a dose of 5–10 mg/kg per day
according to urinary oxalate (review in [2]). Response to
pyridoxine may, therefore, help to preclude or delay the
progression to ESRD; the patients most likely to respond
are those with homozygous Gly170Arg or Phe152Ile
mutations, who also experience preserved renal function
over time under adequate treatment [5].
The treatment of stones should avoid open and percuta-
neous surgery, because further renal lesions will alter GFR.
The use of ureteroscopy and ureteral JJ stent is very helpful.
Extra-corporeal shock-wave lithotripsy is an available
option for selected patients, but mobilisation of extensive
parenchymal crystal deposits in the case of nephrocalci-
nosis may induce parenchymal scarring.
Conventional haemodialysis is not suitable for patients
who have reached ESRD, because it cannot overcome the
continuous excess production of oxalate, so that there are
limited indications [2]: (1) if the diagnosis of PH1 has not
been established; (2) in small children with infantile
oxalosis waiting for organ transplantation; (3) in prepara-
tion for kidney transplant, whether before of after liver
transplantation, in order to deplete oxalate from the body;
(4) following isolated kidney or combined liver–kidney
transplantation with any delay in achieving optimal renal
function, as a temporary adjunct in the case of high oxalate
burden, or with transient loss of transplant function; (5)
very exceptionally, in older patients if the only alternative is
no dialysis; (6) in developing countries, in the absence of
appropriate organ transplantation.
Liver transplantation is a form of gene therapy as well as
enzyme replacement therapy as it will supply the missing
enzyme in the correct organ (liver), cell (hepatocyte) and
intracellular compartment (peroxisome) [6]. The ultimate goal
of organ replacement is to change a positive whole-body
accretion rate into a negative one by reducing endogenous
oxalate synthesis and providing good oxalate clearance via
either native or transplanted kidney. The largest experience
has been obtained with a synchronous combined liver–kidney
transplantation, leading to acceptable results. The option of a
metachronous procedure (liver transplantation followed by
kidney transplantation) should be kept in mind according to
local experience and when the prospective waiting time is
Fig. 2 Infrared spectroscopy
examination of a urinary stone.
The spectrum of monohydrated
calcium oxalate (whewellite) is
shown in a patient with further
demonstration of primary
hyperoxaluria type 1
Pediatr Nephrol (2010) 25:415–424 417long enough to jeopardise both patient quality of life and
survival (review in [2]).
Prospects for restoration of defective enzymatic activity
through the use of chemical chaperones and hepatocyte cell
transplantation, or recombinant gene therapy for enzyme
replacement is encouraging for correcting the underlying
genetic defect without exposure to the life-long risks
associated with organ transplantation [7].
Primary hyperoxaluria type 2
PH2 (MIM 260000) has been documented in fewer than 50
patients and is characterised by the absence of GR/HPR
activity both in the liver and lymphocytes. There is
evidence for autosomal recessive transmission, and the
gene GRHPR has been located on chromosome 9cen [8].
The median age at onset is 1–2 years, and the classical
presentation is urolithiasis (whewellite), including hematuria
and obstruction, but stone-forming activity is lower than in
PH1. GFR is usually maintained during childhood, and
systemic involvement is exceptional [9].
In the presence of hyperoxaluria without hyperglycolu-
ria, a diagnosis of PH2 should be considered, especially
when AGT activity is normal. However, hyperoxaluria in
PH2 tends to be less pronounced than in PH1. The
biochemical hallmark is the increased urinary excretion of
L-glycerate, but the definitive diagnosis requires DNA
analysis and screening of the most frequent mutation
(c.103delG).
The overall long-term prognosis is better than for PH1.
ESRD occurs in 12% of patients, between 23 years and
50 years of age. As in PH1, supportive treatment includes
high fluid intake, crystallisation inhibitors and prevention
of complications. Kidney transplantation has been per-
formed in some patients, often leading to recurrence,
including hyperoxaluria and L-glycerate excretion [9].
Inborn errors of amino acid metabolism
The tubular reabsorption rate of most amino acids approx-
imates 99%, so that their global clearance ranges between
0.5 ml/min and 2.5 ml/min. They use active trans-tubular
transport, which is usually associated with active sodium
transport; such tubular transport may be specific to either
one single amino acid (e.g. glycine, histidine) or to a group
of amino acids (e.g. cystine, lysine, ornithine and arginine).
There are some physiological variations in amino acid
reabsorption, such as physiological immaturity (iminogly-
cinuria or cystinuria–lysinuria during the first 6 months of
life) or circadian rhythm (increased urinary elimination
during daytime and after each meal).
Fanconi syndrome
Hyperaminoaciduria (mainly histidine, glycine, serine,
alanine and glutamine) is a marker of proximal tubular
dysfunction together with variable increased urinary excre-
tion of glucose, phosphate, bicarbonate, potassium, calcium,
uricacid,carnitine,etc.SuchFanconisyndromemayeitherbe
primary (idiopathic primary Fanconi syndrome), or it may
occur secondarily to various inherited metabolic disorders,
i.e. cystinosis (cystinosin), tyrosinaemia type 1 (fumarylaceto-
acetate hydrolase), fructose intolerance (fructose 1,6-bisphos-
phate aldolase), Wilson disease (copper-transporting P type
ATPase, ATP7B gene), glycogen storage disease type 1
(glucose-6-phosphatase), respiratory chain disorders, Fan-
coni–Bickel syndrome (GLUT-2), lysinuric protein intolerance
(y
+LAT1 protein encoded by SLC7A7 gene), etc.
In such condition, nephrolithiasis/nephrocalcinosis can
be secondary to either hypercalciuria or conservative
measures of Fanconi syndrome, including phosphate and
vitamin D that may be responsible for repeated episodes of
iatrogenic hypercalciuria.
Cystinuria
Cystinuria (MIM 220100) is an autosomal recessive inherited
aminoaciduria that leads to recurrent nephrolithiasis with a
prevalence between 1 in 2,500 and 1 in 100,000; cystine
represents 4–8 % of all renal stones in children in France [3].
In this disease, the epithelial transport of dibasic amino acids
(cystine, ornithine, arginine and lysine) by the proximal
tubule and the small intestine is impaired. However, because
of its poor solubility at normal or low urinary pH, only
cystine (1 mmol=250 mg) results in urinary precipitation
and recurrent calculi, e.g. at a pH of 7, the solubility
threshold of cystine is 1 mmol/l and 2 mmol/l at a pH of 7.5.
Type A disease (45% of patients with cystinuria) is
found in families in whom heterozygotes are unaffected
and is caused by mutations of SLC3A1 on chromosome
2p21 (glycoprotein rBAT protein), whereas type B (53%
of patients with cystinuria) is caused by mutations of
SLC7A9 on chromosome 19q12-13 (b
0,+AT protein),
where 80–90% of heterozygotes demonstrate dibasic
aminoaciduria [10, 11]. Type AB is found in 2% of
patients with cystinuria, with one mutation in each gene.
Both proteins belong to the family of light subunits of
heteromultimeric amino acid transporters. Patients may
carry either homozygous or compound heterozygous
mutations. In addition, there are some reports of patients
with the hypotonia–cystinuria syndrome, which is caused
by micro-deletions of two contiguous genes, SLC3A1 and
PRELP, on chromosome 2; patients present with general-
ised hypotonia at birth, failure to thrive, growth retardation
a n dc y s t i n u r i at y p eA[ 12].
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ages, while, in others, the first stone may form in the
second or third decade of life, but stone events do not
correlate with the urinary excretion of amino acids. Indeed,
some infants may exhibit a severe form of cystinuria with
transient renal impairment then followed by a partial
resolution by 2–4 years of age; this may be due to an
increased expression of SLC3A1 mRNA in postnatal versus
fetal kidney [13]. Later in life, cystinuria phenotype seems
more severe in male patients than in female patients [11]. In
the long term, renal function may be impaired in some
patients, mainly those who have not complied with
treatment; such an outcome is never due to extensive
nephrocalcinosis but to repeated episodes of obstruction
and infection.
Cystinuria may be diagnosed by the finding of hexagonal
crystals (Fig. 3), a stone, or by increased urinary cystine
levels. Quantitative determination of urinary amino acids
by ion exchange chromatography usually shows levels of
cystine above 100 μmol/mmol creatinine (normal < 30),
together with isolated increase of the other dibasic amino
acids. A prenatal approach to cystinuria has been suggested
by the presence of hyperechoic colon during the third
trimester of pregnancy, which may be due to the presence
of large amounts of cystine in the colon wall [14].
Cystine stones are often resistant to extra-corporeal
shock-wave lithotripsy, so that percutaneous surgery and
ureteroscopy are the preferred techniques for stone extrac-
tion. Local treatment using percutaneous nephrostomy
together with in-situ infusion of bicarbonate and N-
acetylcysteine may allow stone dissolution in selected
patients [15]. The medical preventive management includes
(1) high fluid intake (1.5–2 l/m
2 per day) well distributed
over day- and night-time; (2) limited sodium intake,
because of competition transport of sodium against amino
acids at the apical side of the tubular cell; (3) urine
alkalinisation using orally administered potassium citrate
(or sodium bicarbonate); (4) low protein diet in order to
limit methionine (precursor of cystine)-rich food (eggs,
fish, meat, cheese); (5) when such measures are ineffective
in preventing stone recurrence or dissolving pre-existing
stones, agents such as α-mercapto-propionylglycine
(tiopronine, 20 mg/kg per day) or D-penicillamine (20 mg/kg
per day) are capable of forming highly soluble mixed
disulphides with cystine moieties, especially when cystine
excretion is more than 3 mmol per day; such components
are 50-times more soluble than cystine [16, 17]. The
follow-up of these patients is based on urine volume (target
urine density<1010), urine pH (target 7.5<pH<8), free
urinecystineconcentration(target<1mmol/lor<100μmol/mol
creatinine), renal ultrasonography and, sometimes, urinary
sodium (in order to estimate sodium intake) and crystal volume
assessment (target<3,000 μm
3/mm
3)[ 18]. Therefore, the
treatment must be personalised, and the amount of drug
required is dependent on body size.
Inborn errors of purine and pyrimidine metabolism
Inborn errors of purine and pyrimidine metabolism may be
associated with nephrolithiasis of various composition and
pathophysiology (Table 2, Fig. 4). They represent 1–3% of
renal stones in children in France [3]. All these calculi are
primarily radiolucent, but they can be identified by
ultrasound, which usually does not show any kind of
nephrocalcinosis.
Most inborn errors of purine and pyrimidine metabolism
are characterised by hyperuricosuria, but they are also
characterised by calcium stone formation; uric acid excretion
rate decreases from childhood towards adulthood and varies
with age (normal urinary uric acid is less than 100 μmol/kg
per day; normal urate:creatinine ratio (in mmol:mmol)
ranges from 1.6 in infants to 0.4 in adolescents), and the
highest fractional excretion is found in neonates. Indeed,
hyperuricosuria per se enhances calcium oxalate precipita-
tion by lowering its solubility [19]. In addition, urate
crystals induce heterogeneous nucleation of calcium oxa-
late, and hyperuricosuria can adsorb urinary inhibitors of
calcium crystallisation [20]. Many children with isolated
hyperuricosuria may present with haematuria without evi-
dence of stones, but patients with inborn errors of purine and
pyrimidine metabolism exhibit extra-renal involvement,
which is a major part of the prognosis of the disease [21].
The solubility of uric acid is dependent on urine pH, so
that alkalinisation (aiming at a pH between 6 and 7) may
prevent further stone formation or allow the dissolution of
existing calculi. This should be added to hydration, aiming
at a target concentration of urinary uric acid below 2.5
mmol/l. In addition, a low purine/nucleoprotein diet is
recommended.
Fig. 3 Examination of urinary sediment discloses a hexagonal crystal
of cystine
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Phosphoribosyl pyrophosphate (PRPP) synthetase superac-
tivity (MIM 300661) is of X-linked inheritance. In pedigrees
with associated sensorineural deafness, heterozygous female
subjects have been found with gout and hearing impairment
[22].
The disease usually shows in young male patients with
gouty arthritis and uric acid nephrolithiasis, sometimes
leading toESRD.Plasmauricacidisincreasedand mayreach
600–900 μmol/l (normal adult values 170–320 μmol/l), and
urine uric acid is also increased so that the urinary uric acid to
creatinine ratio approximates 2.5 mmol/mmol (normal adult
values 0.2–0.3 mmol/mmol). Such uric acid overproduction
may appear during infancy, together with neurological
abnormalities, i.e. sensorineural deafness, hypotonia, motor
delay, ataxia and autistic features [22].
The enzyme forms PRPP from ribose-5-phosphate and
adenosine triphosphate (ATP) (Fig. 4). PRPP synthetase is
highly regulated; various genetic regulatory and catalytic
defects may lead to superactivity, resulting in increased
generation of PRPP [21]. PRPP synthetase superactivity is
one of the few examples of enhanced enzyme activity. The
pathophysiology of neurological involvement is unknown.
Thediagnosisisbasedonkineticsstudiesoftheenzymeon
erythrocytes and cultured fibroblasts in a limited number of
Table 2 Pathophysiology and stone composition of inborn defects of purine and pyrimidine metabolism (PRPP phosphoribosyl pyrophosphate,
HGPRT hypoxanthine-guanine phosphoribosyl transferase, APRT adenine phosphoribosyl transferase, UMP uridine monophosphate)
Stone composition Pathophysiology
Defect in purine
nucleotide synthesis
Defect in purine
catabolism
Defect in
purine salvage
Defect in pyrimidine
metabolism
Uric acid PRPP synthetase superactivity HGPRT deficiency
Xanthine Xanthine oxidase deficiency
2,8-Dihydroxyadenine APRT deficiency
Orotic acid UMP synthase deficiency
a
aNo nephrolithiasis
Nucleic acids
IMP
Adenine Hypoxanthine Xanthine Guanine
Uric acid
AMP GMP
PRPP
Sugar
APRT HGPRT
XO
XO
PRPS
HGPRT
AMP Adenosine   monophosphate
APRT Adenine phosphoribosyl transferase
GMP Guanosine monophosphate
HGPRT Hypoxanthine-guanine phosphoribosyl transferase
IMP Inosine monophosphate
PRPP 5-phosphoribosyl 1-pyrophosphate
PRPS PRPP synthetase
XO Xanthine-oxidase
Nucleic acids
Fig. 4 Simplified pathways of
purine metabolism
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HGPRT deficiency, which may give similar clinical signs.
The treatment is based on allopurinol, which inhibits
xanthine oxidase and results in a decrease in the production
of uric acid and its replacement by both hypoxanthine and
xanthine (Fig. 4), which are more soluble than uric acid.
The initial dosage is 10–20 mg/kg per day for children and
2–10 mg/kg per day for adults, which should be further
adjusted to the minimum required to maintain normal
plasma uric acid concentration, and reduced for patients
with impaired renal function. In some patients with major
increase in de novo synthesis, xanthine calculi can be formed
during allopurinol therapy [23]. Additional measures to
prevent crystallisation are recommended: a low purine diet (free
oforganmeats,fishsuchasanchovy,herring,mackerel,salmon,
sardines and tuna, dried beans and peas), high fluid intake and
alkalinisation aiming at a urinary pH of 6.0 to 7.0 (sodium
bicarbonate, potassium citrate or other citrate mixtures).
Adequate control of plasma uric acid (target<400 μmol/l) is
required in order to control gout and renal involvement, but it
has no influence on neurological outcome.
Hypoxanthine-guanine phosphoribosyl transferase
deficiency: Lesch–Nyhan syndrome
Deficiency of hypoxanthine-guanine phosphoribosyl trans-
ferase (HGPRT) activity is an inborn error of purine
metabolism associated with uric acid overproduction (Fig. 4)
and various degrees of neurological involvement, depending
on the degree of enzyme deficiency (MIM 300322). The
prevalence is estimated at 1 in 380,000 live births in Canada
and 1 in 235,000 in Spain [24].
Neurological manifestations include severe action dysto-
nia, choreo-athetosis, ballismus, cognitive and attention
deficit, and self-destructive behaviour (biting of fingers and
lips leading to mutilating loss of tissue). The most severe
presentations are known as Lesch–Nyhan syndrome;
patients are healthy at birth, and diagnosis can be accom-
plished when psychomotor delay becomes apparent. Where-
as most patients have an intelligence quotient (IQ) around
50, some display normal intelligence. Half of the patients
have seizures [21]. Partial HGPRT-deficient patients present
these symptoms with a different intensity, and in the least
severe forms symptoms may be either unapparent or limited
to gout.
Uric acid overproduction is found in all HGPRT-
deficient patients and is associated with nephrolithiasis
and gout. Orange crystals may be identified in diapers
during the first weeks of life, and some patients may show
neonatalacuterenalfailureduetocrystalnephropathy[25]. In
the absence of specific treatment, patients exhibit repeated
uric acid nephrolithiasis, with the risk of obstruction and
further chronic renal insufficiency.
Overproduction of uric acid is due to increased quantity of
PRPP, which is not utilised at the level of HGPRT but leads to
de novo synthesis (Fig. 4). However, the pathophysiology of
neurological involvement is not clear and may be based on
dopaminergic dysfunction.
The disease is of X-linked recessive inheritance, thus
boys are affected whereas girls are usually asymptomatic
carriers. Human HGPRT is encoded by a single structural
gene at Xq26. To date, more than 300 mutations have been
identified.
The diagnosis is based on clinical and biochemical
findings [hyperuricaemia (concentrations up to 1,000 μmol/
l) and hyperuricosuria (concentrations of 150–850 μmol/kg
per 24 h), together with psychomotor delay], and enzymatic
(determination of HGPRT activity in red blood cells or
fibroblasts) and molecular tests [24]. Molecular diagnosis
allows faster and more accurate carrier and prenatal
diagnosis. Prenatal diagnosis can be performed from
chorionic villous cells obtained at 10–12 weeks gestation
or from amniotic cells obtained by amniocentesis at 15–18
weeks gestation.
Uric acid overproduction can be managed by allopurinol
treatment at a dose of 4–10 mg/kg per day (without
exceeding 300 mg per day because of the risk of oxypurinol
crystallisation), with a target concentration of plasma uric
acid below 400 μmol/l [26]. Indeed, allopurinol dosage
must be carefully adjusted in order to avoid increased urine
xanthine and further iatrogenic xanthine crystal formation
(normal urine xanthine 0.03±0.01 mmol/mol creatinine)
[27]. The lack of precise understanding of neurological
involvement has precluded the development of useful
therapies. Spasticity and dystonia can be managed with
diazepam, baclofen, haloperidol and/or barbiturates. In
addition, adequate physiotherapy is recommended. Self-
injurious behaviour must be managed by a combination of
physical restraints (elbow splints, lip guards and even tooth
extraction) and behavioural and pharmaceutical treatments.
Some new therapeutic options have been proposed to
improve self-mutilation, such as chronic stimulation of the
globus pallidus or the oral use of nifedipine. Bone marrow
transplantation may restore erythrocyte HGPRT, but it has
no influence on neurological symptoms.
Adenine phosphoribosyl transferase deficiency
The deficiency may lead to clinical manifestations in early
childhood, but it can also remain silent for decades (MIM
102600). Symptoms include the passage of crystals, gravel,
and stones. Such nephrolithiasis isresponsiblefor abdominal
colic, dysuria, haematuria, urinary tract infection, and,
sometimes, acute anuric renal failure. 2,8-dihydroxyadenine
is found in crystals and stones and can be distinguished from
uric acid stones only by infrared spectrophotometry.
Pediatr Nephrol (2010) 25:415–424 421The deficiency results in suppression of adenine (Fig. 4),
and adenine is oxidised by xanthine oxidase into 2,8-
dihydroxyadenine, which is a very poorly soluble com-
pound. Such a deficiency can be complete or partial (only
in Japanese patients).
Adenine phosphoribosyl transferase (APRT) deficiency
is of autosomal recessive inheritance, and the gene has been
located on chromosome 16q24. All Japanese patients carry
the same mutation, while approximately 30 mutations have
been reported in Caucasians.
The identification of 2,8-dihydroxyadenine requires spe-
cific diagnostic tests, i.e. infrared spectrometry, mass
spectrometry and X-ray crystallography. The deficit is
confirmed by assessment of APRTactivity in red blood cells
(normal enzyme activity in red blood cells=15–35 U/l) [28].
Allopurinol should be given to patients with symptoms
in order to inhibit the formation of 2,8-dihydroxyadenine.
In addition, dietary purine restriction and high fluid intake
are recommended, but alkalinisation of the urine is not
advised, since the solubility of 2,8-dihydroxyadenine is
unchanged up to pH 9 [21].
The ultimate outcome depends on renal function at the
time of diagnosis, and delayed identification of the disease
may lead to chronic renal insufficiency.
Xanthine-oxidase deficiency
Two deficiencies of xanthine oxidase (or dehydrogenase) are
known: isolated hereditary xanthinuria (type 1, with neph-
rolithiasis) and combined xanthine oxidase and sulphite
oxidase deficiency (type 2, with prominent neurological
involvement). Isolated xanthine oxidase deficiency (MIM
278300) can be asymptomatic, but one-third of affected
patients suffer from kidney stones. Xanthine stones are not
visible on X-ray and may appear at any age; some patients
also present with myopathy associated with crystalline
xanthine deposits.
The metabolic deficiency results in the replacement of
uric acid by hypoxanthine and xanthine as the end products
of purine catabolism (Fig. 4). The gene of isolated xanthine
oxidase deficiency is located on chromosome 2p22; only
two mutations, resulting in a nonsense substitution and a
termination codon, have been reported [29].
Plasma concentration of uric acid is low (<60 μmol/l)
and may become undetectable if the patient is on a low-
purine diet. Urinary uric acid is dramatically reduced and
replaced by hypoxanthine and xanthine. The enzymatic
assessment requires liver or intestinal mucosa, the only
tissues which normally contain significant amounts of
xanthine oxidase [21].
Isolated xanthine oxidase is usually a benign condition,
but recurrent renal stones should be prevented by the use of
a low-purine diet and by large fluid intake.
Hereditary renal hypo-uricaemia
Familial renal hypo-uricaemia (MIM 220150) is a very
rare disease caused by mutations in the SLC22A12 gene
[30]. The disease is due to a defect in the tubular
reabsorption of urate, such as in Dalmatian dogs, some-
times leading to uric acid nephrolithiasis. Some patients
may present with exercise-induced acute renal failure.
Prevention of stone formation may be achieved by
hydration and alkalinisation.
Glycogen storage disease type 1
Glycogen storage disease type 1 (GSD-1) is mainly due to a
deficiency in the catalytic subunit of glucose-6-phosphatase
(GSD-1a or von Gierke disease, MIM 232200, G6PT1 gene
mutation, 80% of all GSD-1) and sometimes to a deficiency
of the endoplasmic reticulum glucose-6-phosphate translo-
case (MIM 232220, GSD-1b, 20% of GSD-1). Both GSDs
involve the liver and the kidney, and patients present with
hepatomegaly, short stature, hypoglycaemia, lactacidaemia
and hyperlipidaemia; neutropenia and infections are specif-
ic of GSD-1b [31]. GSD-1a and GSD-1b are autosomal
recessive disorders; the gene encoding glucose-6-phospha-
tase (G6PC) has been identified on chromosome 17q21,
and the gene encoding glucose-6- phosphate translocase has
been found on chromosome 11q23.
Nephrocalcinosis and nephrolithiasis may occur only
during the course of GSD-1 and not in other types of GSD,
involving both hypercalciuria/hypocitraturia and hyperur-
icaemia [31]. Part of the glucose-6-phosphate excess is
metabolised by pentose phosphate shunt, therefore leading
to hyperuricaemia. In addition, renal distal tubular dysfunc-
tion can occur, even in patients with adequate metabolic
control, and may lead to a combination of low citrate
excretion and hypercalciuria [32]. Normally, urinary citrate
excretion increases with age, but, in patients with GSD-1a,
both calcium and citrate excretion are inversely correlated
with age. Such reduction in citrate excretion may be due to
chronic lactic acidosis secondary to deficient glucose
production. Indeed, chronic metabolic acidosis is able to
increase citrate uptake by the proximal tubular cell in intra-
cellular acidosis and by direct influence in the proximal
tubular transport of citrate by the brush border membrane in
response to low luminal pH [33, 34]. The long-term
combination of chronic acidosis and hypercalciuria may
explain the relevance of severe osteoporosis in adults with
GSD-1a.
Oral citrate supplementation may be able to prevent and
ameliorate nephrocalcinosis and the development of nephroli-
thiasis [32]. Sodium salts should be avoided, to limit
additional calcium excretion. In addition, such patients should
422 Pediatr Nephrol (2010) 25:415–424be given allopurinol to control plasma uric acid and thiazides,
in order to control hypercalciuria and prevent worsening of
osteoporosis.
Other rare conditions associated with nephrolithiasis
Deficiency of 5-oxoprolinase
Very few patients have been reported with a hereditary defect
in5-oxoprolinase(MIM260005),adisorderinthemetabolism
of glutathione, which is of autosomal recessive inheritance
[35]. Renal stone formation may lead to diagnosis, which can
also include chronic enterocolitis, hypoglycaemia and mild
mental retardation. Patients excrete abnormal amounts of
5-oxoproline. No specific treatment has been proposed, and
prognosis remains to be established.
Glucose-galactose malabsorption (disorder of glucose
transport)
Severe nephrocalcinosis may be found in glucose-galactose
malabsorption (SGLT1 deficiency) in association with
hypercalcaemia [36].
3-Methylglutaconic aciduria
3-Methylglutaconic aciduria (branched-chain organic
aciduria, MIM 250950) is characterised by urinary
excretion of 3-methylglutaconyl-CoA and 3-methylglutaric
acids. Such biochemical abnormality is frequently found
during urine organic acid analysis and is often regarded as
a marker of mitochondrial disorder. Some patients have
been reported with nephrocalcinosis and sometimes
medullary cysts [37].
Blue-diaper syndrome
Blue-diaper syndrome (Drummond syndrome, MIM 211000)
is characterised by hypercalcaemia, nephrocalcinosis and
indicanuria. The disease is associated with a defect in
intestinal tryptophane absorption that leads to blue colour-
ation of the urine after contact with the air. The transmission
may be autosomal recessive or X-linked, and the defect may
be due to mutations in the LAT2 or TAT1 genes [38].
Conclusion
Nephrolithiasis related to inherited metabolic diseases is a
very rare condition that may require specific measures.
However, the overall outcome usually depends on extra-
renal involvement in relation to the metabolic defect.
Questions
(Answers appear following the reference list)
1. In the presence of hyperoxaluria, the following findings
are suggestive of primary hyperoxaluria type 1:
a. monohydrated oxalate crystals in the urine
b. elevated glycerate in the urine
c. elevated glyoxylate in the urine
d. elevated glycolate in the urine
e. early nephrocalcinosis with GFR impairment
2. Cystinuria
a. is due to a defect in the cystinosin transport protein
b. can give symptoms in any kind of obligate
heterozygotes
c. can be symptomatic in infants
d. is often responsible for nephrocalcinosis
e. has poor results for stone treatment with extra-
corporeal shock-wave lithotripsy
3. Uric acid is the major component of stones in the
following diseases:
a. Fanconi syndrome
b. phosphoribosylpyrophosphatesynthetasesuperactivity
c. Lesch–Nyhan syndrome
d. adenine phosphoribosyl transferase (APRT) deficiency
e. xanthine oxidase deficiency
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